Literature DB >> 25524385

mTOR signaling, Tregs and immune modulation.

Nicole M Chapman1, Hongbo Chi.   

Abstract

Foxp3(+) Tregs are central regulators of immune tolerance. As dysregulated Treg responses contribute to disease pathogenesis, novel approaches to target the immunomodulatory functions of Tregs are currently under investigation. mTORC1 and mTORC2 are therapeutic targets of interest. Recent studies revealed that mTOR signaling impacts conventional T-cell homeostasis, activation and differentiation. Moreover, mTOR controls the differentiation and functions of Tregs, suggesting that its activity could be targeted to modulate Treg responses. Here, we summarize how Tregs suppress immune responses, their roles in disease development and methods used to alter their functions therapeutically. We also discuss the diverse effects exerted by mTOR inhibition on the development, homeostasis, and functions of conventional T cells and Tregs. We conclude with a discussion of how modulation of mTOR activity in Tregs may be therapeutically beneficial or detrimental in different disease settings.

Entities:  

Keywords:  T cells; immunotherapy; mTORC1; rapamycin; regulatory T cells

Mesh:

Substances:

Year:  2014        PMID: 25524385      PMCID: PMC4291176          DOI: 10.2217/imt.14.84

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  139 in total

1.  Rapamycin inhibits differentiation of Th17 cells and promotes generation of FoxP3+ T regulatory cells.

Authors:  Heather Kopf; Gonzalo M de la Rosa; O M Zack Howard; Xin Chen
Journal:  Int Immunopharmacol       Date:  2007-09-20       Impact factor: 4.932

2.  Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition.

Authors:  Yanping Wang; Tim Sparwasser; Robert Figlin; Hyung L Kim
Journal:  Cancer Res       Date:  2014-02-26       Impact factor: 12.701

3.  Modulation of tryptophan catabolism by regulatory T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Kwang Woo Hwang; Ciriana Orabona; Carmine Vacca; Roberta Bianchi; Maria Laura Belladonna; Maria Cristina Fioretti; Maria-Luisa Alegre; Paolo Puccetti
Journal:  Nat Immunol       Date:  2003-10-26       Impact factor: 25.606

4.  Anergic T cells are metabolically anergic.

Authors:  Yan Zheng; Greg M Delgoffe; Christian F Meyer; Waipan Chan; Jonathan D Powell
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

5.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

6.  Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines.

Authors:  Y Wang; X-Y Wang; J R Subjeck; P A Shrikant; H L Kim
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

7.  Helios expression is a marker of T cell activation and proliferation.

Authors:  Tatiana Akimova; Ulf H Beier; Liqing Wang; Matthew H Levine; Wayne W Hancock
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

8.  Essential role for CD103 in the T cell-mediated regulation of experimental colitis.

Authors:  Oliver Annacker; Janine L Coombes; Vivianne Malmstrom; Holm H Uhlig; Tim Bourne; Bengt Johansson-Lindbom; William W Agace; Christina M Parker; Fiona Powrie
Journal:  J Exp Med       Date:  2005-10-10       Impact factor: 14.307

9.  Rasgrp1 mutation increases naive T-cell CD44 expression and drives mTOR-dependent accumulation of Helios⁺ T cells and autoantibodies.

Authors:  Stephen R Daley; Kristen M Coakley; Daniel Y Hu; Katrina L Randall; Craig N Jenne; Andre Limnander; Darienne R Myers; Noelle K Polakos; Anselm Enders; Carla Roots; Bhavani Balakishnan; Lisa A Miosge; Geoff Sjollema; Edward M Bertram; Matthew A Field; Yunli Shao; T Daniel Andrews; Belinda Whittle; S Whitney Barnes; John R Walker; Jason G Cyster; Christopher C Goodnow; Jeroen P Roose
Journal:  Elife       Date:  2013-12-12       Impact factor: 8.140

10.  PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.

Authors:  David K Finlay; Ella Rosenzweig; Linda V Sinclair; Carmen Feijoo-Carnero; Jens L Hukelmann; Julia Rolf; Andrey A Panteleyev; Klaus Okkenhaug; Doreen A Cantrell
Journal:  J Exp Med       Date:  2012-11-26       Impact factor: 14.307

View more
  52 in total

1.  High frequency of central memory regulatory T cells allows detection of liver recipients at risk of early acute rejection within the first month after transplantation.

Authors:  Francisco Boix-Giner; Olga Millan; David San Segundo; Pedro Muñoz-Cacho; Esther Mancebo; Santiago Llorente; Lourdes Rafael-Valdivia; Antoni Rimola; Emilio Fábrega; Anna Mrowiec; Luis Allende; Alfredo Minguela; Jose M Bolarín; Estela Paz-Artal; Marcos López-Hoyos; Mercé Brunet; Manuel Muro
Journal:  Int Immunol       Date:  2015-08-12       Impact factor: 4.823

Review 2.  mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Authors:  Shi-Yong Sun
Journal:  Front Med       Date:  2020-11-09       Impact factor: 4.592

Review 3.  Regulatory T Cell Plasticity and Stability and Autoimmune Diseases.

Authors:  Runze Qiu; Liyu Zhou; Yuanjing Ma; Lingling Zhou; Tao Liang; Le Shi; Jun Long; Dongping Yuan
Journal:  Clin Rev Allergy Immunol       Date:  2020-02       Impact factor: 8.667

4.  Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues.

Authors:  Margaret M Lowe; Ian Boothby; Sean Clancy; Richard S Ahn; Wilson Liao; David N Nguyen; Kathrin Schumann; Alexander Marson; Kelly M Mahuron; Gillian A Kingsbury; Zheng Liu; Priscila Munoz Sandoval; Robert Sanchez Rodriguez; Mariela L Pauli; Keyon Taravati; Sarah T Arron; Isaac M Neuhaus; Hobart W Harris; Esther A Kim; Uk Sok Shin; Matthew F Krummel; Adil Daud; Tiffany C Scharschmidt; Michael D Rosenblum
Journal:  JCI Insight       Date:  2019-12-19

5.  Anti-inflammatory Roles of Glucocorticoids Are Mediated by Foxp3+ Regulatory T Cells via a miR-342-Dependent Mechanism.

Authors:  Dongkyun Kim; Quang Tam Nguyen; Juyeun Lee; Sung Hwan Lee; Allison Janocha; Sohee Kim; Hongnga T Le; Nina Dvorina; Kelly Weiss; Mark J Cameron; Kewal Asosingh; Serpil C Erzurum; William M Baldwin; Ju-Seog Lee; Booki Min
Journal:  Immunity       Date:  2020-07-23       Impact factor: 31.745

6.  Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.

Authors:  C Liu; H Liu; C Lu; J Deng; Y Yan; H Chen; Y Wang; C-L Liang; J Wei; L Han; Z Dai
Journal:  Clin Exp Immunol       Date:  2019-08-26       Impact factor: 4.330

Review 7.  Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?

Authors:  Anabelle Visperas; Dario A A Vignali
Journal:  J Immunol       Date:  2016-11-15       Impact factor: 5.422

8.  [Rapamycin alleviates inflammation by up-regulating TGF-β/Smad signaling in a mouse model of autoimmune encephalomyelitis].

Authors:  Zhenfei Li; Lingling Nie; Liping Chen; Yafei Sun; Li Guo
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-01-30

Review 9.  Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors.

Authors:  David J Lee; Howard J Lee; Jocelyn R Farmer; Kerry L Reynolds
Journal:  Curr Cardiol Rep       Date:  2021-07-01       Impact factor: 2.931

Review 10.  New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.

Authors:  Matthias Waldner; Daniel Fantus; Mario Solari; Angus W Thomson
Journal:  Br J Clin Pharmacol       Date:  2016-03-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.